Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Tilki, 2015, Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy, J Urol, 193, 484, 10.1016/j.juro.2014.08.096

Maurer T, Robu S, Schottelius M, et al. (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.03.013.

Giannarini, 2018, Will image-guided metastasis-directed therapy change the treatment paradigm of oligorecurrent prostate cancer?, Eur Urol, 74, 131, 10.1016/j.eururo.2018.03.021

Budaus, 2016, Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy, Eur Urol, 69, 393, 10.1016/j.eururo.2015.06.010

Mandel P, Tilki D, Chun FK, et al. Accuracy of (68)Ga-prostate-specific membrane antigen positron emission tomography for the detection of lymph node metastases before salvage lymphadenectomy. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.07.025.

Steuber T, Jilg C, Tennstedt P, et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.02.015.

Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004

Tilki, 2013, 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent, Eur Urol, 63, 792, 10.1016/j.eururo.2012.08.003

Cornford, 2017, EAU-ESTRO-SIOG Guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, 71, 630, 10.1016/j.eururo.2016.08.002